CHESTERFIELD, United Kingdom, Dec. 5, 2016 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it received a perfect score of 100 percent on the 2017 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related to lesbian, gay, bisexual and transgender (LGBT) workplace equality, administered by the Human Rights Campaign (HRC) Foundation. Mallinckrodt joins the ranks of 517 major U.S. businesses which also earned top marks this year.
"We are committed to and believe strongly in the power of equality, both in its importance within our company and its positive difference within our communities," said Mallinckrodt President and Chief Executive Officer Mark Trudeau. "At Mallinckrodt, inclusion and diversity are at the core of who we are. As we build a leading specialty pharmaceutical company with a portfolio of innovative therapies that deliver value for patients, we are strengthened by the varied identities, experiences, cultures and views of our employees. On behalf of the thousands of Mallinckrodt employees around the world, we are honored to earn this recognition from the Human Rights Campaign Foundation."
The 2017 CEI rated 1,043 businesses in the report, which evaluates LGBT-related policies and practices including non-discrimination workplace protections, domestic partner benefits, transgender-inclusive health care benefits, competency programs, and public engagement with the LGBT community. Mallinckrodt's efforts in satisfying the CEI's criteria results in a 100 percent ranking and the designation as a Best Place to Work for LGBT Equality.
The HRC Foundation is the educational arm of America's largest civil rights organization working to achieve equality for lesbian, gay, bisexual, transgender and queer people. HRC envisions a world where LGBTQ people are embraced as full members of society at home, at work and in every community.
For more information on the 2017 Corporate Equality Index, or to download a free copy of the report, visit www.hrc.org/cei.
Mallinckrodt strives to make inclusion and diversity an integral part of its culture. This past October, Mallinckrodt's Inclusion and Diversity (I&D) Council ranked sixth on the list of top 25 U.S. organizations to earn the 2016 Employee Resource Group (ERG) & Council Honors Award at the 8th Annual ERG & Council Honors Award™ ceremony, held at the 2016 ERG & Council Conference in Las Vegas.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Daniel J. Speciale, CPA
Director, Investor Relations
Senior Communications Manager
Chief Public Affairs Officer
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-pharmaceuticals-earns-top-marks-in-2017-corporate-equality-index-300373035.html
SOURCE Mallinckrodt Pharmaceuticals